TITLE

The Iboga Enigma: The Chemistry and Neuropharmacology of Iboga Alkaloids and Related Analogs

AUTHOR INFORMATION

Rishab N. Iyer,[1†] David Favela,[1†] Guoliang Zhang,[1†] David E. Olson[1,2,3]*

AFFILIATIONS

[1] Department of Chemistry, University of California, Davis, One Shields Avenue, Davis, CA 95616, USA
[2] Department of Biochemistry & Molecular Medicine, School of Medicine, University of California, Davis, 2700 Stockton Blvd, Suite 2102, Sacramento, CA 95817, USA
[3] Center for Neuroscience, University of California, Davis, 1544 Newton Ct, Davis, CA 95618, USA
† These authors contributed equally to this work
* deolson@ucdavis.edu

SUPPLEMENTARY INFORMATION

Table S1:

Compound	Plant Source	Plant Tissue	Region	Characterization Data
9	*Ervatamia officinalis*	Twigs and Leaves	China	^{1}H, ^{13}C, COSY, NOESY, HMBC, MS, X-ray, ECD, OR, UV, IR
10	*Ervatamia officinalis*	Twigs and Leaves	China	^{1}H, ^{13}C, COSY, NOESY, HMBC, MS, X-ray, ECD, OR, UV, IR
11	*Ervatamia officinalis*	Twigs and Leaves	China	^{1}H, ^{13}C, COSY, NOESY, HMBC, MS, X-ray, ECD, OR, UV, IR
12	*Ervatamia hainanensis*	Aerial Parts	China	^{1}H, ^{13}C, COSY, DEPT, HSQC, HMBC, OR, IR, UV, X-ray
13	*Tabernaemontana divaricata*	Twigs and Leaves	China	^{1}H, ^{13}C, COSY, HMBC, ROESY, MS, X-Ray, UV, OR
14	*Ervatamia officinalis*	Twigs and Leaves	China	^{1}H, ^{13}C, COSY, NOESY, HMBC, MS, X-ray, ECD, OR, UV, IR
15	*Tabernaemontana hystrix*	Root Bark	Brazil	^{1}H, ^{13}C, COSY, HMBC, HMQC, MS, OR, IR
16	*Tabernaemontana inconspicua*	Stems	Cameroon	^{1}H, ^{13}C, COSY, HMBC, MS

|				
17	*Tabernaemontana contorta Stapf*	Fruits	Cameroon	^{1}H, ^{13}C, COSY, HMBC, NOESY, MS, OR
18	*Ervatamia officinalis*	Twigs and Leaves	China	^{1}H, ^{13}C, COSY, NOESY, HMBC, MS, X-ray, ECD, OR, UV, IR
19	*Ervatamia hainanensis*	Twigs and Leaves	China	^{1}H, ^{13}C, DEPT, COSY, NOESY, HSQC, X-Ray, MS, IR, OR, ECD
20	*Ervatamia hainanensis*	Twigs and Leaves	China	^{1}H, ^{13}C, DEPT, COSY, NOESY, HSQC, X-Ray, MS, IR, OR, ECD
21	*Tabernaemontana corymbosa*	Stem Bark	Malaysia	^{1}H, ^{13}C, COSY, HMQC, HMBC, MS, OR, UV, IR, X-Ray
22	*Ervatamia hainanensis*	Aerial Parts	China	^{1}H, ^{13}C, COSY, DEPT, HSQC, HMBC, OR, IR, UV, X-ray
23	*Ervatamia hainanensis*	Aerial Parts	China	^{1}H, ^{13}C, COSY, DEPT, HSQC, HMBC, OR, IR, UV, X-ray
24	*Ervatamia pandacaqui*	Twigs and Leaves	China	[1]H, ^{13}C, NOESY, MS, OR, UV
25	*Tabernaemontana corymbosa*	Bark	Malaysia	^{1}H, ^{13}C, COSY, HMBC, HRMS, OR, X-ray
26	*Tabernaemontana corymbosa*	Bark	Malaysia	^{1}H, ^{13}C, COSY, HMBC, MS, OR, X-ray
27	*Tabernaemontana corymbosa*	Stem Bark	Malaysia	^{1}H, ^{13}C, COSY, HMBC, HSQC, NOE, MS, X-Ray, OR, UV, IR, ECD
28	*Tabernaemontana corymbosa*	Ground Leaf and Stem Bark	Malaysia	^{1}H, ^{13}C, COSY, HMBC, NOE, MS, X-Ray, OR, UV, IR
29	*Tabernaemontana corymbosa*	Stem Bark	Malaysia	^{1}H, ^{13}C, COSY, HMBC, HSQC, NOE, MS, X-Ray, OR, UV, IR
30	*Tabernaemontana corymbosa*	Stem Bark	Malaysia	^{1}H, ^{13}C, COSY, HMBC, HSQC, NOE, MS, OR, UV

|				
31	*Tabernaemontana corymbosa*	Stem Bark	Malaysia	^{1}H, ^{13}C, COSY, HMBC, HSQC, NOE, MS, X-Ray, OR, UV, IR, ECD
32	*Tabernaemontana corymbosa*	Stem Bark	Malaysia	^{1}H, ^{13}C, COSY, HMBC, HSQC, NOE, MS, OR, UV, IR, ECD
33	*Ervatamia officinalis*	Twigs and Leaves	China	^{1}H, ^{13}C, COSY, HMBC, NOE, MS, ECD, IR, UV, OR
34	*Ervatamia officinalis*	Twigs and Leaves	China	^{1}H, ^{13}C, COSY, HMBC, NOE, MS, ECD, IR, UV, OR
35	*Tabernaemontana corymbosa*	Stem Bark	Malaysia	^{1}H, ^{13}C, COSY, HMQC, HMBC, MS, OR, UV, IR, X-Ray
36	*Tabernaemontana divaricata*	Branches and Leaves	China	^{1}H, ^{13}C, HMBC, ROESY, MS, OR, UV
37	*Ervatamia officinalis*	Twigs and Leaves	China	^{1}H, ^{13}C, COSY, NOESY, HMBC, MS, X-ray, ECD, OR, UV, IR
38	*Ervatamia hainanensis*	Twigs and Leaves	China	^{1}H, ^{13}C, DEPT, COSY, NOESY, HSQC, X-Ray, MS, IR, OR, ECD
39	*Ervatamia hainanensis*	Twigs and Leaves	China	^{1}H, ^{13}C, DEPT, COSY, NOESY, HSQC, X-Ray, MS, IR, OR, ECD
40	*Ervatamia hainanensis*	Twigs and Leaves	China	^{1}H, ^{13}C, DEPT, COSY, NOESY, HSQC, X-Ray, MS, IR, OR, ECD
41	*Ervatamia pandacaqui*	Twigs and Leaves	China	^{1}H, ^{13}C, NOESY, MS, OR, UV
42	*Tabernaemontana divaricata*	Branches and Leaves	China	^{1}H, ^{13}C, HMBC, ROESY, MS, OR, UV
43	*Ervatamia hainanensis*	Aerial Parts	China	^{1}H, ^{13}C, COSY, DEPT, HSQC, HMBC, OR, IR, UV, X-ray
44	*Tabernaemontana divaricata*	Branches and Leaves	China	^{1}H, ^{13}C, HMBC, ROESY, MS, OR, UV

45	*Tabernaemontana divaricata*	Twigs and Leaves	China	^{1}H, ^{13}C, COSY, HMBC, DEPT, MS, ECD, OR, UV, IR
46	*Tabernaemontana divaricata*	Twigs and Leaves	China	^{1}H, ^{13}C, COSY, HMBC, DEPT, MS, ECD, OR, UV, IR
47	*Ervatamia hainanensis*	Twigs and Leaves	China	^{1}H, ^{13}C, DEPT, COSY, NOESY, HSQC, X-Ray, MS, IR, OR, ECD
48	*Tabernaemontana divaricata*	Twigs and Leaves	China	^{1}H, ^{13}C, COSY, HMBC, ROESY, MS, X-Ray, UV, OR
49	*Ervatamia officinalis*	Twigs and Leaves	China	^{1}H, ^{13}C, COSY, NOESY, HMBC, MS, X-ray, ECD, OR, UV, IR

Table S1. Sources and characterization data available for newly isolated iboga alkaloids. The available NMR data is listed. OR = optical rotation, ECD = electronic circular dichroism, MS = mass spectrometry, UV = UV/Vis spectroscopy, IR = infrared spectroscopy, X-Ray = X-ray crystallography.

Table S2:

| Compound	Structure	Efficacy Data	Safety Data
(-)-Ibogaine (**1**)		NMDA IC_{50} = 1.11 μM[1] Muscle AChR IC_{50} = 17 μM[2] Human $\alpha 3\beta 4$ AChR IC_{50} = 0.95 μM[3] MOR IC_{50} = 3.76 μM[4] KOR IC_{50} = 29.8 μM[1] MOR K_i = 3.76 μM[5] KOR K_i = 3.77 μM[6] DAT IC_{50} = 4.11 μM[4] SERT IC_{50} = 0.59 μM[4] DAT K_i = 1.98 μM[7] SERT K_i = 0.5487 μM M[7] D1 IC_{50} = >10 μM[4] D2 IC_{50} = >10 μM[4] D3 IC_{50} = >10 μM[4] σ_1 K_i = 8.554 μM[8] σ_2 K_i = 0.201 μM[8] Reduces opioid self-administration[9] Reduces cocaine self-administration[9] Reduces alcohol consumption[10] Reduces nicotine preference[11]	Tremorigenic[12] Cerebellar toxicity[13] hERG IC_{50} = 3.53 μM[14]
(-)-Noribogaine (**2**)		NMDA IC_{50} = 5.48 μM[1] KOR IC_{50} = 0.28 μM[1] Human $\alpha 3\beta 4$ AChR IC_{50} = 6.82 μM[3] NMDA IC_{50} = 31.41 μM[15] DAT K_i = 2.05 μM[7] SERT K_i = 0.0407 μM[7] σ_1 K_i = 15.006 μM[8] σ_2 K_i = 5.226 μM[8] MOR K_i = 0.16 μM[5] KOR K_i = 0.96 μM[6] Reduces opioid self-administration[16] Reduces cocaine self-administration[16] Reduces alcohol consumption[17]	Not tremorigenic[12] hERG IC_{50} = 2.86 μM[14]

		Reduces nicotine self-administration[18]	
(±)-Ibogamine (**81**)		NMDA IC_{50} = 5.52 μM[1] σ_1 K_i = 1.835 μM[8] σ_2 K_i = 0.137 μM[8] Reduces opioid self-administration[9] Reduces cocaine self-administration[9]	Not tremorigenic[9]
(±)-Coronaridine (**4**)		NMDA IC_{50} = 6.24 μM[1] σ_1 K_i = 35.688 μM[8] σ_2 K_i = >26 μM[8] Reduces opioid self-administration[9] Reduces cocaine self-administration[9]	Not tremorigenic[9]
(-)-Tabernanthine (**5**)		NMDA IC_{50} = 10.5 μM[1] σ_1 K_i = 2.872 μM[8] σ_2 K_i = 0.194 μM[8] Reduces opioid self-administration[9] Reduces cocaine self-administration[9]	Tremorigenic[19]
(±)-**190**		NMDA IC_{50} = 67.9 μM[1]	Unknown
(±)-**191**		NMDA IC_{50} = 252 μM[1] Reduces opioid self-administration[9] Reduces cocaine self-administration[9]	Tremorigenic[9]
(-)-**192**		NMDA IC_{50} = 179 μM[1] KOR IC_{50} = 16.7 μM[1]	Unknown
(±)-18-MC (**193**)		Muscle AChR IC_{50} = 6.8 μM[2] Human $\alpha3\beta4$ AChR IC_{50} = 1.47 μM[3] Human $\alpha4\beta2$ AChR IC_{50} = 6.3 μM[20] Human $\alpha7$ AChR IC_{50} = 0.95 μM[20] Reduces opioid self-administration[21] Reduces cocaine self-administration[21] Reduces alcohol consumption[22] Reduces nicotine self-administration[23] Reduces nicotine preference[11]	Not tremorigenic[21] No cerebellar toxicity[21] hERG IC_{50} > 50 μM[14]
(±)-18-MAC (**194**)		Muscle AChR IC_{50} = 5.9 μM[2] Human $\alpha3\beta4$ AChR IC_{50} = 2.62 μM[3] Human $\alpha4\beta2$ AChR IC_{50} = 20.7 μM[20] Human $\alpha7$ AChR IC_{50} = Inactive[20]	Unknown
(+)-Catharanthine (**7**)		Muscle AChR IC_{50} = 20 μM[2] Human $\alpha3\beta4$ AChR IC_{50} = 0.68 μM[3] Human $\alpha4\beta2$ AChR IC_{50} = 12.6 μM[20] Human $\alpha7$ AChR IC_{50} = 21.8 μM[20]	Unknown
(±)-**195**		NMDA IC_{50} = 31.5 μM[24] KOR IC_{50} = 19.5 μM[24] DAT IC_{50} = 4.4 μM[24] SERT IC_{50} = 0.5 μM[24]	Unknown

(±)-**196**		KOR IC_{50} = 29.8 μM[25] Analgesic[25]	Not tremorigenic[25]
(±)-XL-008 (**197**)		Induces GDNF release[26]	Unknown
(±)-**198**		KOR IC_{50} = 21.2 μM[4] MOR IC_{50} = 3.1 μM[4] DAT IC_{50} = 0.18 μM[4] SERT IC_{50} = 0.19 μM[4] D1 IC_{50} = 20 μM[4] D2 IC_{50} = 27.2 μM[4] D3 IC_{50} = 4.2 μM[4]	Unknown
(±)-**199**		NMDA IC_{50} = 42 μM[4] KOR IC_{50} = 1.3 μM[4] MOR IC_{50} = 2.2 μM[4] DAT IC_{50} = 0.14 μM[4] SERT IC_{50} = 0.30 μM[4] D1 IC_{50} = 3 μM[4] D2 IC_{50} = 5.0 μM[4] D3 IC_{50} = 0.6 μM[4]	Unknown
(±)-**200**		NMDA IC_{50} = 46.6 μM[4] KOR IC_{50} = 12.5 μM[4] MOR IC_{50} = 5.0 μM[4] DAT IC_{50} = 0.21 μM[4] SERT IC_{50} = 4.30 μM[4] D1 IC_{50} = 5 μM[4] D2 IC_{50} = 3.5 μM[4] D3 IC_{50} = 2.0 μM[4]	Unknown
(±)-**201**		NMDA IC_{50} = 32 μM[4] KOR IC_{50} = 16.2 μM[4] MOR IC_{50} = 3.1 μM[4] DAT IC_{50} = 0.25 μM[4] SERT IC_{50} = 1.10 μM[4] D1 IC_{50} = 5 μM[4] D2 IC_{50} = 3.1 μM[4] D3 IC_{50} = 0.6 μM[4]	Unknown
(±)-**202**		NMDA IC_{50} = 81 μM[4] KOR IC_{50} = 15.9 μM[4] MOR IC_{50} = 54.5 μM[4] DAT IC_{50} = 0.25 μM[4] SERT IC_{50} = 1.20 μM[4] D1 IC_{50} = 70 μM[4] D2 IC_{50} = 5.0 μM[4] D3 IC_{50} = 2.0 μM[4]	Unknown
(±)-**203**[27]		Unknown	Unknown
(±)-**204**[28]		Unknown	Unknown

(±)-**205**[27]		Unknown	Unknown
(±)-**206**[29]		Unknown	Unknown
(±)-**207**[29]		Unknown	Unknown
(±)-**208**[30]		Unknown	Unknown
(±)-**209**[31]		Unknown	Unknown

Table 4. Structures of ibogalogs. References disclosing efficacy or safety data are indicated. For compounds lacking biological data, a reference for the synthesis of compound is shown next to the compound number.

Supplementary References

1. Layer, R. T.; Skolnick, P.; Bertha, C. M.; Bandarage, U. K.; Kuehne, M. E.; Popik, P. Structurally Modified Ibogaine Analogs Exhibit Differing Affinities for NMDA Receptors. Eur. J. Pharmacol., 1996, 309, 159–165.
2. Arias, H. R.; Feuerbach, D.; Targowska-Duda, K. M.; Jozwiak, K. Structure–Activity Relationship of Ibogaine Analogs Interacting with Nicotinic Acetylcholine Receptors in Different Conformational States. Int. J. Biochem. Cell Biol., 2011, 43, 1330–1339.
3. Arias, H. R.; Targowska-Duda, K. M.; Feuerbach, D.; Jozwiak, K. Coronaridine Congeners Inhibit Human α3β4 Nicotinic Acetylcholine Receptors by Interacting with Luminal and Non-Luminal Sites. Int. J. Biochem. Cell Biol., 2015, 65, 81–90.
4. Efange, S. M. N.; Mash, D. C.; Khare, A. B.; Ouyang, Q. Modified Ibogaine Fragments: Synthesis and Preliminary Pharmacological Characterization of 3-Ethyl-5-Phenyl-1,2,3,4,5,6-Hexahydroazepino[4,5-b] Benzothiophenes. J. Med. Chem., 1998, 41, 4486–4491.
5. Pablo, J. P.; Mash, D. C. Noribogaine Stimulates Naloxone-Sensitive [35S]GTPγS Binding. NeuroReport, 1998, 9, 109–114.
6. Pearl, S. M.; Herrick-Davis, K.; Teitler, M.; Glick, S. D. Radioligand-Binding Study of Noribogaine, a Likely Metabolite of Ibogaine. Brain Res., 1995, 675, 342–344.
7. Mash, D. C.; Staley, J. K.; Baumann, M. H.; Rothman, R. B.; Hearn, W. L. Identification of a Primary Metabolite of Ibogaine That Targets Serotonin Transporters and Elevates Serotonin. Life Sci., 1995, 57, 45–50.
8. Bowen, W. D.; Vilner, B. J.; Williams, W.; Bertha, C. M.; Kuehne, M. E.; Jacobson, A. E. Ibogaine and Its Congeners Are σ2 Receptor-Selective Ligands with Moderate Affinity. Eur. J. Pharmacol., 1995, 279, 1–3.
9. Glick, S.; Kuehne, M.; Raucci, J.; Wilson, T.; Larson, D.; Keller, R.; Carlson, J. Effects of Iboga Alkaloids on Morphine and Cocaine Self-Administration in Rats: Relationship to Tremorigenic Effects and to Effects on Dopamine Release in Nucleus Accumbens and Striatum. Brain Res., 1994, 657, 14–22.
10. Rezvani, A. H.; Overstreet, D.; Leef, Y.-W. Attenuation of Alcohol Intake by Ibogaine in Three Strains of Alcohol-Preferring Rats. Pharmacol. Biochem. Behav., 1995, 52, 615–620.

11. Glick, S. D.; Maisonneuve, I. M.; Visker, K. E.; Fritz, K. A.; Bandarage, U. K.; Kuehne, M. E. 18-Methoxycoronardine Attenuates Nicotine-Induced Dopamine Release and Nicotine Preferences in Rats. Psychopharmacology, 1998, 139, 274–280.
12. Baumann, M. H.; Pablo, J. P.; Ali, S. F.; Rothman, R. B.; Mash, D. C. Noribogaine (12-Hydroxyibogamine): A Biologically Active Metabolite of the Antiaddictive Drug Ibogaine. Ann. N. Y. Acad. Sci., 2000, 914, 354–368.
13. Ohearn, E.; Molliver, M. Degeneration of Purkinje Cells in Parasagittal Zones of the Cerebellar Vermis after Treatment with Ibogaine or Harmaline. Neuroscience, 1993, 55, 303–310.
14. Alper, K.; Bai, R.; Liu, N.; Fowler, S. J.; Huang, X.-P.; Priori, S. G.; Ruan, Y. HERG Blockade by Iboga Alkaloids. Cardiovasc. Toxicol., 2016, 16, 14–22.
15. Staley, J. K.; Ouyang, Q.; Pablo, J.; Hearn, W. L.; Flynn, D. D.; Rothman, R. B.; Rice, K. C.; Mash, D. C. Pharmacological Screen for Activities of 12-Hydroxyibogamine: a Primary Metabolite of the Indole Alkaloid Ibogaine. Psychopharmacology, 1996, 127, 10–18.
16. Glick, S.; Pearl, S.; Cai, J.; Maisonneuve, I. Ibogaine-like Effects of Noribogaine in Rats. Brain Res., 1996, 713, 294–297.
17. Rezvani, A. H.; Mash, D. C.; Hearn, W. L.; Lee, Y. W.; Overstreet, D. H.: Noribogaine, a primary ibogaine metabolite, Reduces alcohol intake in P and Fawn-Hooded rats. Alcohol Clin. Exp. Res., 1995, 19:15A;
18. Chang, Q.; Hanania, T.; Mash, D. C.; Maillet, E. L. Noribogaine Reduces Nicotine Self-Administration in Rats. J. Psychopharmacol., 2015, 29, 704–711.
19. Trouvin, J.-H.; Jacqmin, P.; Rouch, C.; Lesne, M.; Jacquot, C. Benzodiazepine Receptors Are Involved in Tabernanthine-Induced Tremor: in Vitro and in Vivo Evidence. Eur. J. Pharmacol. 1987, 140, 303–309.
20. Arias, H. R.; Jin, X.; Feuerbach, D.; Drenan, R. M. Selectivity of Coronaridine Congeners at Nicotinic Acetylcholine Receptors and Inhibitory Activity on Mouse Medial Habenula. Int. J. Biochem. Cell Biol., 2017, 92, 202–209.
21. Glick, S. D.; Kuehne, M. E.; Maisonneuve, I. M.; Bandarage, U. K.; Molinari, H. H. 18-Methoxycoronaridine, a Non-Toxic Iboga Alkaloid Congener: Effects on Morphine and Cocaine Self- Administration and on Mesolimbic Dopamine Release in Rats. Brain Res., 1996, 719, 29−35.
22. Rezvani, A. H.; Overstreet, D. H.; Yang, Y.; Maisonneuve, I. M.; Bandarage, U. K.; Kuehne, M. E.; Glick, S. D. Attenuation of alcohol consumption by a novel nontoxic ibogaine analogue (18-methoxycoronaridine) in alcohol-preferring rats. Pharmacol. Biochem. Behav. 1997, 58, 615–619.
23. Glick, S. D.; Maisonneuve, I. M.; Dickinson, H. A. 18-MC Reduces Methamphetamine and Nicotine Self-Administration in Rats. Neuroreport, 2000, 11, 2013–2015.
24. Passarella, D.; Barilli, A.; Efange, S. M. N.; Elisabetsky, E.; Leal, M. B.; Lesma, G.; Linck, V. M.; Mash, D. C.; Martinelli, M.; Peretto, I.; Silvani, A.; Danieli, B. Nature-Inspired Indolyl-2-Azabicyclo[2.2.2]Oct-7-Ene Derivatives as Promising Agents for the Attenuation of Withdrawal Symptoms: Synthesis of 20-Desethyl-20-Hydroxymethyl-11-Demethoxyibogaine. Nat. Prod. Res., 2006, 20, 758–765.
25. Banerjee, T. S.; Paul, S.; Sinha, S.; Das, S. Synthesis of Iboga-like Isoquinuclidines: Dual Opioid Receptors Agonists Having Antinociceptive Properties. Bioorg. Med. Chem., 2014, 22, 6062–6070.
26. Gassaway, M. M.; Jacques, T. L.; Kruegel, A. C.; Karpowicz, R. J.; Li, X.; Li, S.; Myer, Y.; Sames, D. Deconstructing the Iboga Alkaloid Skeleton: Potentiation of FGF2-Induced Glial Cell Line-Derived Neurotrophic Factor Release by a Novel Compound. ACS Chem. Biol., 2015, 11, 77–87.
27. Sundberg, R. J.; Amat, M.; Fernando, A. M. Analogs of the Iboga Alkaloids. Synthesis and Reactions of (±)-15-Oxo-20-deethylcoronaridine Derivatives. J. Org. Chem., 1987, 52, 3151–3159.
28. Sundberg, R. J.; Cherney, R. J. Synthesis of Analogs of Iboga Alkaloids. Investigation of Electrophilic, Palladium-Catalyzed and Radical Cyclizations for Preparation of 5,6-Homoiboga Derivatives. J. Org. Chem., 1990, 55, 6028–6037.
29. Kruegel, A. C.; Rakshit, S.; Li, X.; Sames, D. Constructing Iboga Alkaloids via C–H Bond Functionalization: Examination of the Direct and Catalytic Union of Heteroarenes and Isoquinuclidine Alkenes. J. Org. Chem., 2015, 80, 2062–2071.
30. Paul, S.; Pattanayak, S.; Sinha, S. Synthesis of New Series of Iboga Analogues. Tetrahedron, 2011, 52, 6166–6169.
31. Jana, G. K.; Sinha, S. Total Synthesis of Ibogaine, Epiibogaine and Their Analogues. Tetrahedron, 2012, 68, 7155–7165.